208 related articles for article (PubMed ID: 16026311)
21. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Durdagi S; Reis H; Papadopoulos MG; Mavromoustakos T
Bioorg Med Chem; 2008 Aug; 16(15):7377-87. PubMed ID: 18595717
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of ferrocene-based cannabinoid receptor 2 ligands.
Sansook S; Tuo W; Bollier M; Barczyk A; Dezitter X; Klupsch F; Leleu-Chavain N; Farce A; Tizzard GJ; Coles SJ; Spencer J; Millet R
Future Med Chem; 2018 Mar; 10(6):631-638. PubMed ID: 29419319
[TBL] [Abstract][Full Text] [Related]
23. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
25. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
26. Chemical probes for the recognition of cannabinoid receptors in native systems.
Martín-Couce L; Martín-Fontecha M; Palomares O; Mestre L; Cordomí A; Hernangomez M; Palma S; Pardo L; Guaza C; López-Rodríguez ML; Ortega-Gutiérrez S
Angew Chem Int Ed Engl; 2012 Jul; 51(28):6896-9. PubMed ID: 22689411
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB
Morales P; Navarro G; Gómez-Autet M; Redondo L; Fernández-Ruiz J; Pérez-Benito L; Cordomí A; Pardo L; Franco R; Jagerovic N
Chemistry; 2020 Dec; 26(68):15839-15842. PubMed ID: 32794211
[TBL] [Abstract][Full Text] [Related]
28. Methods for the synthesis of cannabinergic ligands.
Thakur GA; Nikas SP; Duclos RI; Makriyannis A
Methods Mol Med; 2006; 123():113-48. PubMed ID: 16506405
[TBL] [Abstract][Full Text] [Related]
29. A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB
Casajuana-Martin N; Navarro G; Gonzalez A; Llinas Del Torrent C; Gómez-Autet M; Quintana García A; Franco R; Pardo L
J Chem Inf Model; 2022 Nov; 62(22):5771-5779. PubMed ID: 36302505
[TBL] [Abstract][Full Text] [Related]
30. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
31. Novel pyrrolocycloalkylpyrazole analogues as CB
Asproni B; Manca I; Pinna G; Cichero E; Fossa P; Murineddu G; Lazzari P; Loriga G; Pinna GA
Chem Biol Drug Des; 2018 Jan; 91(1):181-193. PubMed ID: 28675787
[TBL] [Abstract][Full Text] [Related]
32. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
34. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
[TBL] [Abstract][Full Text] [Related]
35. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.
Pertwee RG; Howlett AC; Abood ME; Alexander SP; Di Marzo V; Elphick MR; Greasley PJ; Hansen HS; Kunos G; Mackie K; Mechoulam R; Ross RA
Pharmacol Rev; 2010 Dec; 62(4):588-631. PubMed ID: 21079038
[TBL] [Abstract][Full Text] [Related]
36. Understanding functional residues of the cannabinoid CB1.
Shim JY
Curr Top Med Chem; 2010; 10(8):779-98. PubMed ID: 20370713
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
38. GPR55 as a new cannabinoid receptor: still a long way to prove it.
Petitet F; Donlan M; Michel A
Chem Biol Drug Des; 2006 Mar; 67(3):252-3. PubMed ID: 16611220
[No Abstract] [Full Text] [Related]
39. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
40. 3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinoid CB1 and CB2 receptors.
Mella-Raipán J; Hernández-Pino S; Morales-Verdejo C; Pessoa-Mahana D
Molecules; 2014 Mar; 19(3):2842-61. PubMed ID: 24603555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
